Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase

Abstract

Taliglucerase alfa is an enzyme replacement therapy approved for treatment of Gaucher disease (GD) in children and adults in several countries. This multicenter extension study assessed the efficacy and safety of taliglucerase alfa in pediatric patients with GD who were treatment-naïve (n = 10) or switched from imiglucerase (n = 5). Patients received taliglucerase alfa 30 or 60 U/kg (treatment-naïve) or the same dose as previously treated with imiglucerase every other week. In treatment-naïve patients, taliglucerase alfa 30 and 60 U/kg, respectively, reduced mean spleen volume (− 18.6 multiples of normal [MN] and − 26.0 MN), liver volume (− 0.8 MN and − 0.9 MN), and chitotriosidase activity (− 72.7% and − 84.4%), and increased mean Hb concentration (+ 2.0 g/dL and + 2.3 g/dL) and mean platelet count (+ 38,200/mm3 and + 138,250/mm3) from baseline through 36 total months of treatment. In patients previously treated with imiglucerase, these disease parameters remained stable through 33 total months of treatment with taliglucerase alfa. Most adverse events were mild/moderate; treatment was well tolerated. These findings extend the taliglucerase alfa safety and efficacy profile and demonstrate long-term clinical improvement in treatment-naïve children receiving taliglucerase alfa and maintenance of disease stability in children switched to taliglucerase alfa. Treatment was well-tolerated, with no new safety signals. This study is registered at www.clinicaltrials.gov as NCT01411228. © 2016 Shire Human Genetic Therapies, Inc.